S. Stenning

发表

Adolescents and young adults with a "rare" cancer: getting past semantics to optimal care for patients with germ cell tumors.

C. Rodríguez-Galindo, A. L. Frazier, D. Gershenson, 2014, The oncologist.

Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.

R. Huddart, G. Rustin, P. Vasey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.

R. Huddart, A. Padhani, G. Rustin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The accuracy of volumetric measurement of high-grade gliomas.

R A Chisholm, S. Stenning, T. Hawkins, 1989, Clinical radiology.

Strategies to improve retention in randomised trials

G. Rait, S. Meredith, I. Nazareth, 2013, The Cochrane database of systematic reviews.

Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.

L. Collette, S. Fosså, R. Sylvester, 1999, Journal of the National Cancer Institute.

Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values.

Ewout W Steyerberg, J. Habbema, E. Steyerberg, 2006, Journal of clinical epidemiology.

A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.

N. Bleehen, S. Stenning, S. Stenning, 1991, British Journal of Cancer.

Assessing the potential for prevention or earlier detection of on-site monitoring findings from randomised controlled trials: Further analyses of findings from the prospective TEMPER triggered monitoring study

William J. Cragg, W. Cragg, S. Stenning, 2020, medRxiv.

W. Cragg, S. Stenning, V. Yorke-Edwards, 2020, Clinical trials.

A systematic search for reports of site monitoring technique comparisons in clinical trials

S. Burdett, S. Meredith, J. Tierney, 2012, Clinical trials.

Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but not overall survival: preliminary results of an EORTC/MRC randomized phase III study.

M. Piérart, D. Áfra, O. Witte, 1998 .

Randomized clinical trial of adjuvant radiotherapy and 5‐fluorouracil infusion in colorectal cancer (AXIS)

R. James, J. Northover, R. Gray, 2003, The British journal of surgery.

A medical research council randomized trial in patients with primary cerebral non‐Hodgkin lymphoma

P. Lantos, A. Gregor, N. Bleehen, 2000, Cancer.

An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma.

N. Bleehen, S. Stenning, L. Freedman, 1987, British Journal of Cancer.

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

H. Grabsch, R. Langer, M. Nankivell, 2017, The Lancet. Oncology.

What is the role of radiation-chemotherapy in the radical non-surgical management of carcinoma of the oesophagus? Upper GI Cancer Working Party of the UK Medical Research Council.

P. Price, S. Stenning, P. Hoskin, 1998, British Journal of Cancer.

Radiotherapy for malignant gliomas in the elderly.

M. Brada, S. Stenning, 2003, Seminars in oncology.

Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971)

D. Cunningham, W. Allum, S. Weeden, 2005 .

Summary

S. Stewart, N. Bleehen, J. Hansen, 1966, National Institute Economic Review.

AXIS--a suitable case for treatment. UK Coordinating Committee on Cancer Research (UKCCCR) Colorectal Cancer Subcommittee.

R. James, R. Gray, S. Stenning, 1991, British Journal of Cancer.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

H. Grabsch, D. Alderson, D. Cunningham, 2017, The Lancet. Oncology.

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours

M. Williams, S. Fosså, A. Horwich, 1999, British Journal of Cancer.

Strategies to reduce attrition in randomised trials (Protocol)

G. Rait, J. Darbyshire, S. Meredith, 2011 .

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial

M. Rugge, M. Fassan, M. Nankivell, 2017, JAMA oncology.

Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours.

S. Stewart, N. Bleehen, S. Stenning, 1991, British Journal of Cancer.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

M. S. Lewis, M. Sydes, D. Wright, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Postchemotherapy residual masses in germ cell tumor patients

S. Fosså, A. Horwich, C. Fisher, 1998, Cancer.

Surgical resection with and without chemotherapy in oesophageal cancer

D. Girling, P. Clark, J. Bancewicz, 2002, The Lancet.

Strategies to reduce attrition in randomised trials

G. Rait, S. Meredith, I. Nazareth, 2011, Trials.

Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).

H. Grabsch, R. Langer, M. Nankivell, 2015 .

2201 Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948)

H. Grabsch, D. Alderson, A. Riddell, 2015 .

LBA-03Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072)

H. Grabsch, R. Langer, M. Nankivell, 2015 .

(2017). Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncology (3), 357–370.

D. Alderson, S. Stenning, S. Rowley, 2017 .

Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group.

S. Fosså, A. Horwich, G. Mead, 1998, The Journal of urology.

A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)

R. Huddart, J. Shamash, R. Gabe, 2011, European urology.

A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604).

R. Huddart, J. Shamash, R. Gabe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

L. Collette, S. Fosså, S. Kaye, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma

D. Dearnaley, A. Horwich, R. Huddart, 2013, British Journal of Cancer.

Reply to K.-P. Dieckmann et al

R. Gabe, S. Stenning, T. Oliver, 2011 .

Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).

S. Fosså, A. Horwich, G. Mead, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group.

S. Fosså, A. Horwich, J. Owen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

L. Collette, S. Fosså, N. Aaronson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postchemotherapy Residual Masses in Germ Cell Tumor Patients. Content, Clinical Features, and Prognosis

S. Fosså, A. Horwich, C. Fisher, 1999 .

Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.

A. Horwich, G. Rustin, S. Kaye, 1997, European journal of cancer.

Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials

A. Horwich, C. Meisner, C. Bokemeyer, 2004, British Journal of Cancer.

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma

S. Fosså, D. Dearnaley, A. Horwich, 2000, British Journal of Cancer.

Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

A. Horwich, E. Hall, J. Bliss, 2010 .

The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2.

A. Horwich, G. Mead, G. Daugaard, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

R. Laing, R. Huddart, M. Highley, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin in clinical stage I seminoma: a valuable option for patient management.

R. Gabe, S. Stenning, T. Oliver, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18)

S. Fosså, G. Mead, S. Stenning, 2001 .

The sword of Damocles and the treatment of stage I seminoma.

M. Mason, J. Aparicio, K. Dieckmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report.

S. Fosså, A. Horwich, S. Stenning, 1993, European urology.

GONADOTROPIN AND SEX-HORMONE LEVELS IN TESTIS CANCER-PATIENTS WITH AND WITHOUT CARCINOMA IN-SITU OF THE CONTRALATERAL TESTIS

S. Fosså, A. Horwich, S. Stenning, 1994 .

The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.

N. Bleehen, P. Workman, T. Maughan, 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study Ann Oncol 2002; 13: 1264–1274

M. S. Lewis, M. Sydes, D. Wright, 2002 .

Treatment of gastric cancer - Reply

D. Cunningham, W. Allum, S. Stenning, 2006 .

Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010).

H. Grabsch, M. Nankivell, D. Alderson, 2014 .

Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer

W. Allum, P. Fogarty, S. Stenning, 2008 .

Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.

D. Cunningham, G. Middleton, S. Stenning, 2010 .

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.

W. Allum, P. Clark, J. Bancewicz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to J.A. Ajani

W. Allum, S. Stenning, R. Langley, 2010 .

Consolidation radiotherapy is associated with improved outcomes after chemotherapy for advanced Hodgkin lymphoma: analysis of results from the UKLG LY09 Trial (ISRCTN97144519)

Sydes, J. Radford, S. Stenning, 2008 .

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

C. V. D. van de Velde, M. Nicolson, D. Cunningham, 2006, The New England journal of medicine.

Comparison of outcomes in studies of advanced Hodgkin's lymphoma.

M. Sydes, J. Radford, S. Stenning, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of TP53 mutation status on survival in the MAGIC trial.

M. Nankivell, A. Wotherspoon, D. Cunningham, 2015 .

A randomised trial of Procarbazine, CCNU and Vincristine (PCV) vs Temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12, ISRCTN83176944).

M. Brada, R. Gabe, S. Stenning, 2008 .

Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC / MRC Phase III Study

L. Collette, P. Wilkinson, G. Mead, 2000 .

Implementing monitoring triggers and matching of triggered and control sites in the TEMPER study: a description and evaluation of a triggered monitoring management system

William J. Cragg, M. Sydes, C. Diaz-Montana, 2019, Trials.

Strategies to reduce attrition in randomised trials: a Cochrane systematic review and meta-analysis

G. Rait, S. Meredith, I. Nazareth, 2014 .

Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials.

A. Horwich, C. Bokemeyer, L. Kanz, 2002 .

Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG)- BR05.

P. Lantos, N. Bleehen, F. Senanayake, 1998 .

Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls.

M. Brada, S. Stenning, S. Ashley, 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma.

N. Bleehen, S. Stenning, D. Boote, 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

Richard Sylvester, Andrew Kramar, Madhu Mazumdar, 1997 .

Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).

G. Rustin, G. Mead, R. Coleman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.

A. Horwich, P. Wilkinson, E. Newlands, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party.

N. Bleehen, S. Stenning, L. Freedman, 1989, International journal of radiation oncology, biology, physics.

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

David M. Thomas, M. Brada, S. Stenning, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

D. Pearson, K. Ichimura, M. Brada, 2014, Acta neuropathologica communications.

Prognostic and predictive markers in recurrent high grade glioma ; results from the BR 12 randomised trial

D. Pearson, K. Ichimura, M. Brada, 2014 .

Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma

H. Grabsch, M. A. van de Wiel, B. Ylstra, 2016, Oncotarget.

Intraportal 5-fluorouracil for colorectal cancer: the AXIS trial

R. Gray, S. Stenning, Lore Garten, 1992, The Lancet.

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

K. Hopkins, S. Lee, D. Levy, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Jae-Weon Kim, M. Parmar, H. Earl, 2019, The Lancet.

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.

A. Horwich, S. Kaye, S. Stenning, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up.

S. Fosså, R. Huddart, G. Mead, 2011, Journal of the National Cancer Institute.

Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies.

G. Mead, S. Stenning, 1993, European urology.

ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

J. Brenton, J. Ledermann, I. McNeish, 2017 .

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

D. Pearson, K. Ichimura, M. Brada, 2014, Acta Neuropathologica Communications.

and immunophenotypic criteria (MRC/NCRI LY10 trial) in patients with sporadic Burkitt lymphoma defined using cytogenetic A prospective clinicopathologic study of dose-modified CODOX-M/IVAC

S. Barrans, J. Radford, W. Qian, 2013 .

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

S. Barrans, J. Radford, W. Qian, 2008, Blood.

High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis.

W. Siegert, S. Fosså, J. Beyer, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

Philippe Cornu, A. Karim, M. Piérart, 2002, International journal of radiation oncology, biology, physics.

A randomised trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: EORTC study 22845 with MRC study BR04: an interim analysis

D. Áfra, O. Witte, S. Schraub, 2002 .

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

H. Grabsch, D. Alderson, A. Wotherspoon, 2019, JAMA oncology.

Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).

M. Sydes, J. Radford, S. Stenning, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

K. Maclennan, M. Sydes, J. Radford, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.

H. Grabsch, T. Yoshikawa, M. Nankivell, 2015, The Journal of molecular diagnostics : JMD.

Clinical Trials in Cancer: Principles and Practice

L. Stewart, D. Girling, R. Stephens, 2003 .

Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial

H. Grabsch, D. Treanor, M. Nankivell, 2016, Oncotarget.

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

M. Rugge, M. Fassan, M. Nankivell, 2017, Clinical Cancer Research.

Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review

William J. Cragg, W. J. Cragg, C. Hurley, 2020, medRxiv.

Best practice guidance for the use of strategies to improve retention in randomized trials developed from two consensus workshops

G. Rait, F. Stevenson, J. Tierney, 2017, Journal of clinical epidemiology.

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519).

M. Sydes, J. Radford, P. Johnson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis

G. Rait, S. Meredith, I. Nazareth, 2014, BMJ Open.

Guest editorial: AXIS - a suitable case for treatment

R. James, R. Gray, S. Stenning, 1991 .

A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22.

R. Huddart, A. Padhani, S. Hain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial

Sheena McCormack, Nicola Joffe, S. McCormack, 2012, Clinical trials.

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Frazier, R. Huddart, T. Powles, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214)

G. Mead, P. Fogarty, S. Stenning, 2008 .

Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time

M. C. Parkinson, Jonathan Cohen, S. Stenning, 2005, BJU international.

Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma

D. Berney, R. Huddart, J. Sweet, 2015, Clinical Cancer Research.

Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.

D. Kerr, R. Stephens, J. Ledermann, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trials with moving targets: a commentary on a non-inferiority trial in testicular cancer.

S. Stenning, M. Cullen, 2004, The Lancet. Oncology.

Response of 145 spontaneous canine head and neck tumours to radiation versus radiation plus microwave hyperthermia: results of a randomized phase III clinical study.

N. Bleehen, S. Stenning, N M Bleehen, 1995, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).

Sydes, J. Radford, Paul D. Smith, 2003 .

Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)

R. Huddart, J. Shamash, S. Stenning, 2020, European journal of cancer.

Use of strategies to improve retention in primary care randomised trials: a qualitative study with in-depth interviews

G. Rait, F. Stevenson, S. Meredith, 2014, BMJ Open.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER 2-Positive Gastroesophageal Adenocarcinoma : A Randomized Phase 2 Clinical Trial

H. Grabsch, D. Alderson, W. Allum, 2019 .

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

H. Grabsch, D. Alderson, W. Allum, 2019 .

Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment.

R. Jena, N. Burnet, S. Jefferies, 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis

W. Siegert, S. Fosså, J. Beyer, 1999 .

Improving the acceptability of high-dose radiotherapy by reducing the duration of treatment: accelerated radiotherapy in high-grade glioma.

B. Bell, S. Ashley, M. Brada, 1995, British Journal of Cancer.

A phase II evaluation of human lymphoblastoid interferon (Wellferon) in relapsed high grade malignant glioma

N. Bleehen, S. Stenning, T. Priestman, 1993 .

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

S. Fosså, D. Dearnaley, A. Horwich, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

J. Reis-Filho, A. Wotherspoon, D. Cunningham, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study

P. Quirke, S. Stenning, M. Seymour, 2002, The Lancet.

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

M. Williams, S. Fosså, A. Horwich, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bleomycin in Combination Chemotherapy of Testicular or Extragonadal Germ Cell Tumours: a Review of Published Trials

L. Collette, J. Shamash, M. Mason, 2002 .

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.

R Sylvester, L Collette, L. Collette, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

S. Barrans, W. Qian, G. Mead, 2009 .

Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971)

W. Allum, S. Weeden, S. Stenning, 2005 .

Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group

I. Lewis, J. Whelan, L. Fern, 2008, British Journal of Cancer.

Use of Different Outcome Measures in Randomised Studies of Malignant Glioma can Significantly Alter the Interpretation of Time to Progression: Reanalysis of the MRC BR2 Study

N. Bleehen, J. Chataway, S. Stenning, 1999, Journal of Neuro-Oncology.

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

J. Reis-Filho, A. Wotherspoon, R. Wong, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Thirty years of Medical Research Council randomized trials in solid tumours.

P. Fayers, M. Parmar, L. Stewart, 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council.

J. Cassidy, S. Stenning, M. Seymour, 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials

G. Mead, P. Fogarty, S. Stenning, 2008 .

Molecular markers and the prediction of prognosis and response to therapy in colon cancer

Matthew T. Seymour, Pl Barratt, Sally P. Stenning, 1999 .

Adolescents and Young Adults With a “Rare” Cancer: Getting Past Semantics to Optimal Care for Patients With Germ Cell Tumors

C. Rodríguez-Galindo, A. L. Frazier, D. Gershenson, 2018, The oncologist.